#KRAS 🎯cancer patient group for reliable Knowledge Research Advocacy & Survivorship. Survival of the strategic. #KickCancersKRAS - 🚫 #KRASholes
International, ALL RAS cancers
- Tweets 4,988
- Following 4,917
- Followers 4,149
- Likes 12,407
Pinned Tweet
At @ASCO #GI26 we presented our KRAS KICKERS Trial Finder.
Personalized: KRAS G12D, CRC, US trials
Results (in 4 minutes): 20 trials
go to KRASHUB.ORG
in beta - would love your feedback
abstract
asco.org/abstracts-presentat…
FYI:
G12V - 8 trials for CRC
G12R - 7 trials for CRC
3
3
11
3,584
KRAS Kickers retweeted
A multicenter study led by Mayo Clinic found dividing radiation into several treatments reduced the risk of cancer returning after surgery for brain metastases and improved survival compared with delivering radiation in a single treatment. #ASTRO26
newsnetwork.mayoclinic.org/d…
4
12
811
Announcing the ASCO Quality Care Symposium Featured Voices! Follow them before, during, and after the meeting for expert insights. Join the conversation w/ the official hashtag #ASCOQLTY26.
Registration is open: bit.ly/4xFAmU1
1
6
21
6,014
Andrew J. Aguirre discussed "Targeting RAS in Pancreatic Cancer" in a keynote lecture to open the AACR Conference on New Frontiers in the Biology of and Therapeutic Development for Pancreatic Cancer.
#AACRpan26
1
8
17
6,094
KRAS Kickers retweeted
Lucky to have had the opportunity to work with @WeillCornell Medicine Resident Jennifer Guo who has led the @MSKCancerCenter institutional analysis of ctDNA platform concordance in pancreas cancer KRAS detection. @MSK_DeptOfMed @CpcrMsk
4
18
2,039
KRAS Kickers retweeted
UCSF’s Kevan Shokat, PhD, just won the $1M Stephenson Global Prize for research in pancreatic cancer. He cracked KRAS, a cancer driver long considered “undruggable.” Drugs built on his work now treat lung and pancreatic cancer. ow.ly/xVlw50ZRSXh
ALT Middle-aged man in a blue lab coat smiling while seated in a scientific laboratory setting.
ALT Hand wearing black glove holding five small glass vials with various colored liquids, including pink and orange hues.
15
112
719
75,409
Shout out by@kevansf of website RASinhibitor.com
developed and updated by @papkephd
in the 2026 Stephenson Global Prize Ceremony piped.video/watch?app=deskto…
BTW: Recommended to Dr. Shokat by Dr.
@frankpmccormick
- the Inagural Award winner of the @sgpcri Global Prize
All roads lead to RAS...
rasinhibitors.com
6
15
1,376
We’re proud to announce @kevansf as the recipient of the $1M Stephenson Global Prize for Pancreatic Cancer Research.
His work helped turn “undruggable” KRAS into a target, opening possibilities for people facing pancreatic cancer. And his work is far from finished 🏆
1
9
12
1,243
KRAS Kickers retweeted
Congratulations to the pioneer who started it all with his momentous discovery that mutant KRAS in cancer can be directly targeted and blocked:
@kevansf @UCSFCancer on winning the @sgpcri Global Prize!
KRAS inhibitors for the win!
#AACRPan26
9
53
2,720
for NSLC -here's a list of 7 trials with Daraxonrasib
Includes combo trials for the 30% with either a MTAP deletion or KRAS G12D or G12C mutations.
Trials in: US, Europe (15 countries), Canada, Australia, New Zealand, Hong Kong, Taiwan, South Korea, China, Singapore, Taiwan
clinicaltrials.gov/search?te…
1
5
23
1,323
Of course - many other drugs in trial for NSCLC -
Can use this search - or do a more specific seaerch at krashub.org
clinicaltrials.gov/search?te…
133
Opening November 2026
A Multi-Institutional Phase 2 Evaluation of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
PI: Nilo Azad, MD of @HopkinsMedicine
55 pts
Biliary Tract Cancers
Intrahepatic Cholangiocarcinoma (Icc)
Extrahepatic Cholangiocarcinoma
Gallbladder Carcinoma
Ampulla of Vater Carcinoma
Ampullary Carcinoma
NCT07793253
clinicaltrials.gov/study/NCT…
3
6
3,602
KRAS Kickers retweeted
Thank you. Nearly 600 donors came together to endow the Conquer Cancer – Rachna Shroff, MD, MS, FASCO Endowed Young Investigator Award in Biliary Cancers, for the next generation of researchers❤️. @rachnatshroff Rachna's message: piped.video/YkrLVXVKa_w #ConquerCancer
6
11
788
Expansion to 17 US locations
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Ph 2 trial
60 pts
NCT07446322
An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer
Expansion: 14 US locations, 60 pts
Opened April 2026
Phase 2 trial: NCT07446322
more info @OncLive
FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC
onclive.com/view/fda-grants-…
5
1,034
KRAS Kickers retweeted
Now online: Targeting RAS for Pancreatic Cancer Interception doi.org/10.1158/2159-8290.CD…
3
8
1,316
KRAS Kickers retweeted
Excited to share our new piece in Cancer Discovery on targeting RAS for pancreatic cancer interception, written with amazing Hopkins colleagues @Sandra_Misale @NeehaZaidi @alisonpklein @DrLizJaffee : aacrjournals.org/cancerdisco…
1
12
41
4,661
KRAS Kickers retweeted
Pancreas cancer patients, families, carers &the general public all welcome to a very special event Weds Sept 23 @HerbertParkHotel Ballsbridge 630pm Drs Eileen O’Reilly, New York & Grainne O’Kane, St. Vincent’s will discuss new treatments @ProfJohnCrown ccrt.ie/news-2/?v=2
1
4
175
May this be a message of hope for all who hear Dr. @EileenMOReilly
"Ar scáth a chéile a mhaireann na daoine"
Our Keynote speaker today, Dr Eileen O’Reilly, MSKCC, presenting on advances in pancreatic cancer treatment including the clinical study she led on the targeted therapy daraxonrasib. @ProfJohnCrown @CCRTIreland @DCU_LSI @DCU #TransOncXIX
7
1,101
KRAS Kickers retweeted
đź“şCheck out this lively exchange and summary on pan-RAS inhibition!
🎙️ @DavidHongMD @MDuruisseaux @HHorinouchi
🔥RMC-6236-001: Daraxonrasib (RMC-6236) for previously treated RAS-mutant NSCLC
🆙 @NEJM @COR2EDMedEd
🎯Docetaxel-naïve subgroup (160-220mg): ORR 42%, mPFS 8.3m, mOS 16.0m
đź’ˇRASolve 301 (Phase 3, vs docetaxel) ongoing (NCT06881784)
#LCSM @OncoAlert @Larvol @KRASKickers
cor2ed.com/lung-connect/prog…
nejm.org/doi/full/10.1056/NE…
🧬 Explore the evolving RAS landscape in #NSCLC, including recent daraxonrasib data published in @NEJM
>> Expert perspectives from the US, Europe, and Japan
From Prof. @DavidHongMD, Prof. Michael Duruisseaux (@MDuruisseaux) and Dr Hidehito Horinouchi (@HHorinouchi)
Conversation topics include:
- The diversity of RAS alterations
- The unmet need beyond KRAS G12C
- The emergence of broader RAS-targeted approaches, incl. pan-RAS inhibitors
🎬 Watch the video & view/download the publication snapshot: cor2ed.com/lung-connect/prog…
🤝 Endorsed by @WarOnCancer& @BiomarkerCo
Revolution Medicines has provided a sponsorship agreement towards this independent programme. For HCPs only.
#MedEd #lcsm #MedTwitter #PrecisionOncology
4
3
1,268